Russia Says Vektor’s COVID-19 Vaccination to Enter Second Stage

YERUSHALAYIM -
A medical worker performs a COVID-19 test at a test center at Vnukovo airport outside Moscow, Russia. (AP Photo/Pavel Golovkin, FILE)

The Russian Health Ministry will complete the registration of Vektor Center’s COVID-19 vaccine by 15 October, the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Rospotrebnadzor, said Tuesday.

Rospotrebnadzor announced the successful completion of stage 1 clinical trials for the COVID-19 vaccine developed by the Russian research center Vektor. All the participants had developed antibodies.

After registration, the vaccine will be delivered to 5,000 volunteers. It will also be tested on people over the age of 60. The vaccine does not provide life-long immunity but guarantees immunity for at least six months.

EpiVacCorona, as it is tentatively named, will become Russia’s second COVID-19 vaccine. The first, the Gamaleya Institutes Sputnik V, became the world’s first vaccine against COVID-19.